AbbVie (ABBV) announced that it has completed its acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder. This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $250 from $236 at Raymond James
- 3 Best Dividend Aristocrat Stocks to Buy Now, 10/16/2025
- AbbVie’s Phase 2 Study on CLL/SLL Treatment: Key Updates and Market Impact
- AbbVie’s Venetoclax Study Completion: A Potential Boost for Investors
- Psychedelic: Needham initiates coverage of atai, GH Research, MindMed